Superluminal Medicines Inc.

🚀 Superluminal Medicines Announces Significant Milestone: We’ve Declared our First Development Candidate! 🧬 We’re proud to announce the nomination of our first development candidate (DC), a potentially best-in-class treatment for rare genetic forms of obesity and hypothalamic obesity. The compound is an orally administered, highly selective, biased MC4R agonist which also has strong potential as both a combination therapy and maintenance therapy for general obesity. This milestone represents the power and speed of our drug discovery platform, which is designed to rapidly discover small molecule medicines for a broad range of challenging disease targets. It truly reflects the incredible dedication of our team in pushing the boundaries of science to meet urgent patient needs. Congratulations to the entire team at Superluminal for this important achievement! Visit our website to read the entire press release: https://lnkd.in/g6_JGkWW #DrugDiscovery #DevelopmentCandidate #BiotechMilestone #LifeSciences #TranslationalResearch #PreclinicalDevelopment #BiotechInnovation

Come join our team! #researchassociate #boston #biotech #pharmacology https://lnkd.in/gzFjRhxB

We would like to announce our partnership between Superluminal Medicines, Inc. and Axcelead Drug Discovery Partners, Inc.! The intent is to use the combined capabilities of both organizations to accelerate the discovery and development of innovative small-molecule therapeutics for molecular targets with high unmet medical needs. 👉 Stay tuned for updates as we continue the journey to push the boundaries of innovation in biotech. #DrugDiscovery #BiotechPartnership #InnovationInBiotech #LifeSciences #Collaboration #TherapeuticInnovation

This week our Co-Founder and SVP, Head of Discovery, Ajay Yekkirala attended the 2025 Annual Symposium on Risks and Opportunities of AI in Pharmaceutical Medicine in Portland, ME as one of the speakers on the Keynote Panel. This forum is expected to serve as a platform for distinguished statisticians, data scientists, regulators, and other professionals to address the challenges and opportunities of AI in pharmaceutical medicine; to foster collaboration among industry, academia, regulatory agencies, and professional associations; and to propose recommendations with policy implications for proper implementation of AI in promoting public health. Thank you @Northeastern University for a fantastic experience! #northeasternuniversity #biotech #drugdevelopment

The Superluminal Medicines team has had an exciting few weeks, attending several conferences and participating in a variety of panels! It’s been a truly inspiring experience to be part of such interesting conversations, surrounded by industry experts and innovators. 🟡 Cony D’Cruz, CEO & Founder, attended NVIDIA GTC 2025 conference in March and was a panelist on the “Create, Cure, Care: Reimagining Healthcare – Driving Innovation from Ideation with AI” panel, where he discussed the transformative role of AI in healthcare. 🔵 Ajay Yekkirala, PhD, Head of Discovery & Founder, spoke at the Bio-IT World Conference & Expo in Boston last week, participating in the “Demystifying AI-Real Examples in Drug Development” panel, providing a comprehensive understanding of AI’s potential and its proven return on investment in supporting drug discovery. 🟡 Ryan Bloom, VP of Business Development, recently attended the BMO Obesity Summit in New York, where he connected with leaders in the obesity therapies market, as well as patients and healthcare providers. 🔵 Christina Westgate, Lab Operations Manager, joined the Lab of the Future conference in Boston last month, where she gained insights on cutting-edge research, development, and manufacturing trends shaping the future of science. 🟡 Alix Rouault, Scientist, recently returned from the American Society for Pharmacology and Experimental Therapeutics - ASPET 2025 conference in Oregon, where the latest trends in pharmacology and experimental therapeutics were shared. A big thank you to all these incredible organizations for providing such enriching programs and experiences, enabling the Superluminal team to continue contributing, learning and growing! #GTC2025 #BioITExpo #BMO #LOTF2025 #ASPET2025 #AI #BioPharma #BioTech #DrugDiscovery #SuperluminalMedicines 

We're hiring! Join our team and discover a fulfilling career in biotech. To explore our open positions and learn more about the opportunities available at Superluminal Medicines, please visit our careers page at: https://lnkd.in/eqj7kSh6 #SuperluminalMedicines #Hiring #BioTech

Proud to be included on CB Insights 2024 annual "Digital Health 50", a list of the world's most promising private digital health companies. We are ready for the new year, excited by our growing team, and energized with the work in front of us! Check out the article here: https://lnkd.in/enBp2xTt #SuperluminalMedicines #BioTech #DrugDiscovery #DigitalHealth 

Superluminal Medicines will be attending the 43rd Annual J.P. Morgan Healthcare Conference this January in San Francisco! The team looks forward to connecting with global industry leaders and discussing the latest market trends and medical innovations. We will be onsite all week and look forward to seeing you at #JPM2025 #SuperluminalMedicines #JPMConference 

🚀 Big news at Superluminal Medicines! 🧬 We are thrilled to announce the closing of our $120 million Series A funding round, led by RA Capital Management, with participation from Insight Partners, nVentures (NVIDIA), Gaingels, and new investors Catalio Capital Management, Eli Lilly and Company, and Cooley LLP. This milestone marks a pivotal step in our mission to revolutionize drug discovery through generative biology, chemistry, and machine learning. This investment accelerates our mission to revolutionize drug discovery through our generative biology, chemistry, and machine learning platform. By focusing on GPCR-targeted therapies, we aim to transform how medicines are created with unprecedented speed and accuracy. We’re incredibly excited to continue our journey in transforming medicine and grateful for the support of our investors and incredible team! Stay tuned for more updates as we push the boundaries of drug discovery. 💊🌟 #SeriesAFunding #Biotech #DrugDiscovery #AI4DD #GPCR #Innovation #SuperluminalMedicines For more, check out our press release here: https://lnkd.in/eFTsSKgF